CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual ...

First trial in more than a decade to demonstrate an improvement in outcomes in the 1st-line setting for a broad population of patients with HER2-positive metastatic breast cancer WILMINGTON, ...

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

Based on DESTINY-Breast09 Phase III trial results which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of ...

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. The incidence of infusion reactions was 47.7% (n = 31) with the combination ...

Targeted Oncology ™ originally published this article. This version has been lightly edited. Subcutaneous (SC) trastuzumab induced stromal tumor infiltrating lymphocyte (sTIL) enrichment and favorably ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy ...

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...

SAN ANTONIO — The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere ...

The approval of pertuzumab in free and fixed combination with trastuzumab includes the adjuvant (supportive) therapy of patients with HER2-positive early breast cancer at high risk of recurrence. The ...